NCT04978428View on ClinicalTrials.gov

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Obsessive-Compulsive DisorderTrichotillomania (Hair-Pulling Disorder)Tourette SyndromeHoarding Disorder
Interventions
DRUG

Cannabidiol

Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER